Back to Agenda
Session 7 Track 3: Challenges Around Oligonucleotides Control Strategies
Session Chair(s)
Christian Wetter, PHD
Senior Regulatory Portfolio Director, Roche, Switzerland
Katherine Windsor, PHD
Senior Pharmaceutical Quality Assessor, CDER, Food and Drug Administration, United States
Close to a decade ago, pioneering papers were written on how to set up oligonucleotide control strategies, including proposed impurity grouping. Since then, industry and regulators have expanded their knowledge and their experience in this area. At the same time, the complexity of the oligonucleotide landscape is increasing, in particular because of the development of conjugates and new modifications. Because of the reached level of maturity, oligonucleotides are in scope of new or to-be-revised guidelines. The current session aims at exchanging on experiences and challenges pertaining to oligonucleotide control strategies in general and in view of the changing guideline landscape.
Learning Objective : At the conclusion of this session, participants should be able to:- Understand the current trends pertaining to oligonucleotide control strategies
- Understand the current challenges and how they could influence the content of new guidelines
Speaker(s)
Katharine Duncan, PHD
Senior Pharmaceutical Quality Assessor (SPQA), Office of Product Quality Assessm, FDA, United States
Senior Pharmaceutical Quality Assessor (SPQA), Division of New Drug API, Office of New Drug Products
Lori Troup
Director, Analytical Development, Novo Nordisk, United States
Evaluating the Requirements for Multiple Identity and Purity Methods
Carolyn Mazzitelli, PHD
Executive Director, Analytical Development and Quality Control, Ionis Pharmaceuticals, United States
Speaker
Lubo Nechev, PHD
Chief CMC Officer, Alnylam Pharmaceuticals, United States
Speaker
Have an account?